Literature DB >> 3159480

Changes in the host natural killer cell population in mice during tumor development. 2. The mechanism of suppression of NK activity.

R S Parhar, P K Lala.   

Abstract

Our earlier studies revealed that a rapid and progressive loss of splenic NK activity in mice during the development of a number of transplanted tumors as well as of spontaneous tumors was due to an inactivation of natural killer (NK) lineage cells rather than to their disappearance. The mechanism of this inactivation have now been explored in CBA/J mice receiving transplanted Ehrlich ascites tumors and in C3H/HeJ mice bearing spontaneous mammary tumors or receiving transplants of syngeneic mammary tumor lines of recent origin. A poor activation state or maturation arrest of NK lineage cells due to a low interferon level in vivo was ruled out, since the host NK activity could not be restored after administration of either an interferon inducer poly(I:C) or interferon-alpha, although such treatments enhanced the activity in tumor-free mice by four- to eightfold. Possible presence of host suppressor cells acting on the effector or preeffector stage of NK cells was explored by mixing spleen cells from tumor bearers with normal spleen cells either during the NK assay, or for a 20-hr period of in vitro short-term culture prior to the NK assay. Mixing during the NK assay led to a reduction of NK activity explicable by a simple dilution of active NK cell concentration rather a suppression of active NK cells. On the other hand, a 20-hr coculture of the mixed population at various ratios led to a complete abrogation of the NK activity, indicating that the suppressor cells acted on the preeffector stage of the NK Lineage. A further characterization of suppressor cells revealed that they were (1) contained in the adherent fraction of the spleen of tumor bearers, (2) of monocyte/macrophage morphology, (3) capable of phagocytosing latex particles, and (4) positive for surface Mac-1 antigen, as noted from a radioautographic binding of 125I-labeled monoclonal anti-Mac-1 antibody. The mechanism of the suppression was identified, at least in part, as being mediated by prostaglandin-like molecules, since the presence of indomethacin, a prostaglandin-inhibitor, during the 20-hr coculture period completely abrogated the suppression. Indomethacin exerted no direct effect on the recruitment or killer activity of NK lineage cells in vitro. NK cell suppression may be another normal immunoregulatory mechanism which alters the host-tumor balance in favor of the tumor rather than the host.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159480     DOI: 10.1016/0008-8749(85)90133-9

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  17 in total

1.  N-methylformamide affects spontaneous metastases of 3LL lines and increases natural killer activity of tumor-bearing mice.

Authors:  C Greco; D Del Bufalo; D Giannarelli; M Marangolo; M P Fuggetta; E Bonmassar; G Zupi
Journal:  Clin Exp Metastasis       Date:  1990 Mar-Apr       Impact factor: 5.150

2.  Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.

Authors:  M Rodolfo; C Salvi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2.

Authors:  N K Khoo; F P Chan; M N Saarloos; P K Lala
Journal:  Clin Exp Metastasis       Date:  1992-07       Impact factor: 5.150

5.  Effects of prostaglandin E2, cholera toxin and 8-bromo-cyclic AMP on lipopolysaccharide-induced gene expression of cytokines in human macrophages.

Authors:  W W Zhong; P A Burke; M E Drotar; S R Chavali; R A Forse
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

Review 6.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2.

Authors:  W Budzynski; M Chirigos; E Gruys
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis.

Authors:  M N Saarloos; N K Khoo; P K Lala
Journal:  Clin Exp Metastasis       Date:  1993-05       Impact factor: 5.150

Review 9.  Chemotherapy and immunotherapy of colorectal cancer.

Authors:  G Masucci; P Ragnhammar; J E Frödin; A L Hjelm; P Wersäll; J Fagerberg; A Osterborg; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

10.  Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters.

Authors:  Patrycja Koszałka; Ewa Szmit; Andrzej Myśliwski; Jacek Bigda
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-07-23       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.